Document:

Exhibit
10.1

 

SHAREHOLDER
SUPPORT AGREEMENT AND DEED

 

This
Shareholder Support Agreement and Deed (this “Agreement”) is made and entered into September 29, 2022,
by and among (i) YishengBio Co., Ltd., a Cayman Islands exempted company
(the “Company”), (ii) Summit Healthcare Acquisition Corp.,
a Cayman Islands exempted company (“SPAC”), (iii) Summit
Healthcare Acquisition Sponsor LLC, a Cayman Islands limited liability company (“Sponsor”), (iv) certain
Persons listed on Schedule A hereto (each, a “YSB Shareholder” and collectively, the “YSB Shareholders”),
and (v) certain individuals listed on Schedule B hereto, each of whom is a member of the SPAC Board as of the date hereof (together
with Sponsor, the “SPAC Shareholders” and each, a “SPAC Shareholder”). The YSB Shareholders
and SPAC Shareholders are hereinafter collectively referred to herein as the “Shareholders” and each individually
as a “Shareholder.” Capitalized terms used herein but not defined herein shall have the meaning ascribed to
such terms in the Business Combination Agreement (as defined below).

 

Whereas,
the Company, SPAC, Oceanview Bioscience Acquisition Co., Ltd., a Cayman Islands exempted company (“Merger Sub I”),
and Hudson Biomedical Group Co., Ltd., a Cayman Islands exempted company (“Merger Sub II”), are concurrently
herewith entering into a Business Combination Agreement (the “Business Combination Agreement”) pursuant to
which, among other things, Merger Sub I will merge with and into SPAC (the “First Merger”, the effective time
of the First Merger is referred to herein as the “First Merger Effective Time”), with SPAC being the surviving
entity and a wholly-owned subsidiary of the Company, and SPAC will merge with and into Merger Sub II (the “Second Merger”
and together with the First Merger, the “Mergers”), with Merger Sub II being the surviving entity and a wholly-owned
subsidiary of the Company;

 

Whereas,
each YSB Shareholder is, as of the date of this Agreement, the sole legal owner of such number of ordinary shares of the Company, par
value $0.000005 per share (“YSB Ordinary Shares”) and Series A and/or Series B preferred shares of
the Company, par value $0.000005 per share (“YSB Preferred Shares”) set forth opposite such YSB Shareholder’s
name on Schedule A hereto (such YSB Ordinary Shares and YSB Preferred Shares, together with any other Equity Securities of the Company
acquired by such YSB Shareholder after the date of this Agreement and during the term of this Agreement, are collectively referred to
herein as the “Subject YSB Shares”);

 

Whereas,
each SPAC Shareholder is, as of the date of this Agreement, the sole legal owner of such number of Class B ordinary shares of SPAC,
par value $0.0001 per share (“SPAC Class B Ordinary Shares”) set forth opposite such SPAC Shareholder’s
name on Schedule B hereto (such SPAC Class B Ordinary Shares, together with any other Equity Securities of SPAC acquired by such
SPAC Shareholder after the date of this Agreement and during the term of this Agreement, being collectively referred to herein as the
 “Subject SPAC Shares” and together with the Subject YSB Shares, the “Subject Shares”);

 

Whereas,
SPAC and the SPAC Shareholders entered into that certain Registration and Shareholder Rights Agreement dated as of June 8, 2021
(the “Prior SPAC Agreement”), and the Company, the YSB Shareholders and certain other Persons are parties to
that certain Shareholders’ Agreement relating to the Company dated January 28, 2021 (the “YSB Shareholders Agreement”);

 

Whereas,
(i) the parties to the Prior SPAC Agreement desire to terminate the Prior SPAC Agreement to provide for the terms and conditions
set forth in this Agreement, and (ii) the parties to the Prior YSB Shareholders Agreement desire to amend certain provisions of
the YSB Shareholders Agreement in connection with the transactions contemplated under the Business Combination Agreement and the Mergers
with the terms and conditions set forth in this Agreement; and

 

Whereas,
as a condition to their willingness to enter into the Business Combination Agreement, SPAC and the Company have requested that the Shareholders
enter into this Agreement.

 

    1

     

    

 

Now,
Therefore, in consideration of the premises set forth above, which are incorporated in this Agreement as if fully set forth
below, and the representations, warranties, covenants and agreements contained in this Agreement and the Business Combination Agreement,
and intending to be legally bound hereby, the parties hereto agree as follows:

 

Article I

 

Representations
and Warranties of the PARTIES

 

1.1.            Each
Shareholder hereby, severally (only with respect to such Shareholder) but not jointly, makes the representations and warranties contained
in Schedule C-1 hereto to SPAC and the Company.

 

1.2.            SPAC
hereby makes the representations and warranties contained in Schedule C-2 hereto to the Company and each Shareholder.

 

1.3.            The
Company hereby makes the representations and warranties contained in Schedule C-3 hereto to SPAC and each Shareholder.

 

Article II

 

Agreement
to Vote; Certain Other Covenants of thE SHAREHOLDERS

 

Each
Shareholder, severally (only with respect to such Shareholder) but not jointly, covenants and agrees with SPAC and the Company
during the term of this Agreement as follows (as applicable):

 

2.1.            Agreement
to Vote.

 

(a)            In
Favor of the Mergers and other Transactions. At any meeting of the shareholders of the Company (or
SPAC, as applicable) or any class of shareholders of the Company (or SPAC, as applicable)
(to the extent such Shareholder holds such class of securities) called to seek the Company Shareholders’ Approval (or
the SPAC Shareholders’ Approval, as applicable), or at any adjournment or postponement thereof, or in connection with any
written consent of the shareholders of the Company (or SPAC, as applicable) or any class
of shareholders of the Company (or SPAC, as applicable) (to the extent such Shareholder
holds such class of securities), such Shareholder shall (i) if a meeting is held, appear at such meeting in person or by proxy or
otherwise cause the Subject YSB Shares (or Subject SPAC Shares, as applicable) to be counted
as present at such meeting for purposes of establishing a quorum, and (ii) vote or cause to be voted (including by class vote and/or
written consent, if applicable) the Subject YSB Shares (or Subject SPAC Shares, as applicable)
in favor of granting the Company Shareholders’ Approval (or the SPAC Shareholders’
Approval, as applicable) (in each case, as such terms are defined in the Business Combination Agreement as in effect on the date
hereof) or, if there are insufficient votes in favor of granting the Company Shareholders’ Approval (or
the SPAC Shareholders’ Approval, as applicable), in favor of the adjournment or postponement of such meeting of the shareholders
of the Company (or SPAC, as applicable) to a later date. For the avoidance of doubt, the
obligation to vote in favor of the Mergers and other Transactions pursuant to this Section 2.1(a) shall be deemed satisfied
as to such Shareholder upon the receipt of the Company Shareholders’ Approval (or the SPAC
Shareholders’ Approval, as applicable). For the avoidance of doubt, no YSB Shareholder is agreeing or required under this
Section 2.1(a) to vote in favor of any future amendment, modification or supplement to the Business Combination Agreement or
any other Transaction Document.

 

(b)            Against
Other Transactions. At any meeting of shareholders of the Company (or SPAC, as applicable)
or any class of shareholders of the Company (or SPAC, as applicable) (to the extent such
Shareholder holds such class of securities) or at any adjournment or postponement thereof, or in connection with any written consent
of the shareholders of the Company (or SPAC, as applicable), such Shareholder shall:

 

(a)            if
a meeting is held, appear at such meeting in person or by proxy or otherwise cause the Subject YSB Shares (or
Subject SPAC Shares, as applicable) to be counted as present at such meeting for purposes of establishing a quorum; and

 

    2

     

    

 

(b)            vote
(or cause to be voted) the Subject YSB Shares (or Subject SPAC Shares, as applicable) (including
by proxy, withholding class vote and/or written consent, if applicable) against (i) any business combination agreement, merger agreement
or merger (other than the Business Combination Agreement and the Mergers), scheme of arrangement, business combination, consolidation,
combination, sale of substantial assets, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company
(or SPAC, as applicable) or any public offering of any Equity Securities of the Company
(or SPAC, as applicable) or any of its Subsidiaries or any successor entity of the Company
(or SPAC, as applicable) or such Subsidiary other than any such transaction permitted under
the Business Combination Agreement, (ii) any Company Acquisition Proposal (or SPAC Acquisition Proposal, as applicable),
and (iii) any amendment of the memorandum and articles of association of the Company (or SPAC, as applicable) or other proposal
or transaction involving the Company (or SPAC, as applicable) or any of its Subsidiaries, which amendment or other proposal or transaction
would be reasonably likely to in any material respect impede, interfere with, delay or attempt to discourage, frustrate the purposes
of, result in a breach by the Company (or SPAC, as applicable) of, prevent or nullify any provision of the Business Combination Agreement
or any other Transaction Document, the Mergers, any other Transaction or change in any manner the voting rights of any class of the Company’s
(or SPAC’s, as applicable) share capital.

 

(c)            Revoke
Other Proxies. Such Shareholder represents and warrants that any proxies or powers of attorney heretofore given in respect
of the Subject YSB Shares held by it (or Subject SPAC Shares held by it,
as applicable) that may still be in effect are not irrevocable, and such proxies or powers of attorney have been or are hereby
revoked.

 

2.2.            No
Transfer.

 

(a)            From
the date of this Agreement until the date of termination of this Agreement (including, for the avoidance of doubt, automatic termination
upon the First Merger Effective Time), such Shareholder shall not, directly or indirectly, (i) sell, transfer, tender, grant, pledge,
assign or otherwise dispose of (including by gift, tender or exchange offer, merger or operation of law), encumber, hedge or utilize
a derivative to transfer the economic interest in (collectively, “Transfer”), or enter into any Contract, option
or other arrangement (including any profit sharing arrangement) with respect to the Transfer of, any Subject Shares to any Person other
than pursuant to the Mergers; (ii) grant any proxies (other than as set forth in this Agreement or a proxy granted to a representative
of such Shareholder to attend and vote at a shareholders meeting which is voted in accordance with this Agreement) or enter into any
voting arrangement, whether by proxy, voting agreement, voting trust, voting deed or otherwise (including pursuant to any loan of Subject
Shares), or enter into any other agreement, with respect to any Subject Shares; (iii) take any action that would make any representation
or warranty of such Shareholder herein untrue or incorrect in any material respect, or have the effect of preventing or disabling such
Shareholder from performing its obligations hereunder; or (iv) commit or agree to take any of the foregoing actions or take any
other action or enter into any Contract that would reasonably be expected to make any of its representations or warranties contained
herein untrue or incorrect or would have the effect of preventing such Shareholder from performing any of its obligations hereunder.
Any action attempted to be taken in violation of the preceding sentence will be null and void. Such Shareholder hereby authorizes and
requests SPAC (or the Company, as applicable) to notify SPAC’s (or the Company’s, as applicable) transfer agent or such other
Person with the responsibility for maintaining SPAC’s (or the Company’s, as applicable) register of members that there is
a stop transfer order with respect to all of the Subject Shares (and that this Agreement places limits on the voting of the Subject Shares).
Such Shareholder agrees with, and covenants to, SPAC and the Company that such Shareholder shall not request that SPAC and the Company
register the Transfer (by book-entry or otherwise) of any certificated or uncertificated interest representing any of the Subject Shares
in violation of this Section 2.2.

 

(b)            Section 2.2(a) shall
not prohibit a transfer of Subject Shares by a Shareholder made: (i) in the case of a Shareholder who is not a natural person, by
pro rata distributions from the Shareholder to its members, partners, or shareholders pursuant to the Shareholder’s organizational
documents; (ii) by virtue of applicable law or the Shareholder’s organizational documents upon liquidation or dissolution
of the Shareholder; (iii) in the case of a Shareholder who is not a natural person, to any employees, officers, directors or members
of the Shareholder, or to any Affiliates (as defined below) of the Shareholder; or (iv) upon the consent of the Company and SPAC,
or (v) pursuant to this Agreement, provided, however, that a transfer referred to in Section 2.2(b)(i) to (iv) shall
be permitted only if, as a precondition to such transfer, the transferee agrees in a written document, reasonably satisfactory in form
and substance to the Company and SPAC, to assume all of the obligations of the Shareholder under, and be bound by all of the terms of,
this Agreement. For purposes of this Agreement, “Affiliate” means, with respect to any specified Shareholder, any other person
or entity who or which, directly or indirectly, controls, is controlled by, or is under common control with such specified Shareholder,
including, without limitation, any general partner, limited partner, officer, director, trustee, member, manager, managing member or
employee of such specified Shareholder or any trust for the benefit of any of the foregoing or any Affiliate of the foregoing or any
investment fund or venture capital fund now or hereafter existing that is controlled by or under common control with one or more general
partners, managing members or investment advisers of, or shares the same management company with, such specified Shareholder. For purposes
of this definition, the term “control” when used with respect to any person or entity shall mean the power to direct the
management or policies of such person or entity, directly or indirectly, whether through ownership of voting securities, by contract
or otherwise, and the terms “controlling” and “controlled” shall have meanings correlative to the foregoing.

 

    3

     

    

 

2.3.            Waiver
of Dissenters’ Rights. Such Shareholder hereby irrevocably waives, and agrees not to exercise or assert, any dissenters’
rights under Section 238 of the Companies Act (As Revised) of the Cayman Islands and any other similar statute in connection with
the Mergers and the Business Combination Agreement.

 

2.4.            Waiver
of Anti-Dilution Protection. Such Shareholder (if it is Sponsor) hereby waives, forfeits, surrenders and agrees not to exercise,
assert or claim, to the fullest extent permitted by applicable Law, the ability to adjust the Initial Conversion Ratio (as defined in
the SPAC Charter) pursuant to Article 17.3 of the SPAC Charter in connection with the Transactions. Such Shareholder (if it is Sponsor)
acknowledges and agrees that (i) this Section 2.4 shall constitute written consent waiving, forfeiting and surrendering the
adjustment to the Initial Conversion Ratio pursuant to Article 17.4 of the SPAC Charter in connection with the Transactions; and
(ii) such waiver, forfeiture and surrender granted hereunder shall only terminate upon the termination of this Agreement.

 

2.5.            No
Redemption. (i) Each of the SPAC Shareholders undertakes that, from the date hereof and until the termination
of this Agreement, it will not elect to cause SPAC (or the Company, as applicable) to redeem any Subject Shares now or at any time legally
or beneficially owned by such SPAC Shareholder (whether pursuant to the SPAC Charter, law, contract or otherwise, notwithstanding such
SPAC Shareholder may have rights thereunder), or submit or surrender any of its Subject Shares for redemption; and (ii) each of
the YSB Shareholders undertakes that, from the date hereof and until the termination of this Agreement, it will not elect to cause the
Company to redeem any Subject Shares now or at any time legally or beneficially owned by such YSB Shareholder (whether pursuant to the
Company Charter, law, contract or otherwise, notwithstanding such YSB Shareholder may have rights thereunder), or submit or surrender
any of its Subject Shares for redemption, which shall be without prejudice to any right of such YSB Shareholder to request the Company
to redeem the Subject Shares held by such YSB Shareholder in the event that (x) there is a material breach or default by the Company
or any of its subsidiaries, founders and ordinary shareholders of obligations owed to such YSB Shareholder that is not cured within mutually
agreed period according to the written agreement in effect as of the date hereof, (y) the Founder (as defined in the YSB Shareholders
Agreement) ceases to be employed by or provide services to any Group Company on a full-time basis or (z) the Company redeems the
shares held by any other shareholder of the Company. For the avoidance of doubt, if the Business Combination Agreement is terminated
prior to the Closing, this Section 2.5 shall cease to apply and be of no further force or effect.

 

2.6.            New
Shares. In the event that prior to the Closing (as defined in the Business Combination Agreement) (i) any Equity Securities
of SPAC or the Company are issued or otherwise distributed to a Shareholder pursuant to any share dividend or distribution, or any change
in any of the Subject Shares or other share capital of SPAC or the Company by reason of any share subdivision, recapitalization, consolidation,
exchange of shares or the like, (ii) a Shareholder acquires legal or beneficial ownership of any YSB Ordinary Shares, YSB Preferred
Shares, SPAC Class B Ordinary Shares after the date of this Agreement, or (iii) a Shareholder acquires the right to vote or
share in the voting of any YSB Ordinary Shares, YSB Preferred Shares, SPAC Class B Ordinary Shares after the date of this Agreement
(collectively, the “New Securities”), the terms “Subject Shares” shall be deemed
to refer to and include such New Securities (including all such share dividends and distributions and any securities into which or for
which any or all of the Subject Shares may be changed or exchanged into).

 

2.7.            Shareholders’
Consent, Authorization or Approval. Each Shareholder hereby irrevocably agrees and confirms that, insofar as (i) such Shareholder’s
consent, authorization or approval is required, or (ii) such Shareholder forms part of a class of shareholders of the Company or
SPAC whose consent, authorization or approval is required, in any such case in respect of or in connection with the transactions contemplated
by the Business Combination Agreement and the other Transaction Documents, including pursuant to the YSB Shareholders Agreement, the
SPAC Charter or the Company Charter, such Shareholder hereby grants, provides and gives such consent, authorization or approval, and
all specific resolutions that may be required to have been adopted by such Shareholder or class of shareholders in connection with the
transactions contemplated by the Business Combination Agreement (as the Business Combination Agreement exists on the date hereof) and
the other Transaction Documents (as the Transaction Documents exists on the date hereof) are hereby deemed adopted and approved by such
Shareholder (each as is in effect on the date hereof). For the avoidance of doubt, no Shareholder is providing its consent, authorization
or approval under this Section 2.7 with respect to any future amendment, modification or supplement to the Business Combination
Agreement or any other Transaction Document.

 

    4

     

    

 

2.8.            Joinder
of SPAC Insiders. Each SPAC Insider hereby irrevocably agrees and confirms that it will duly execute and deliver a deed of adherence
in substantially the form of Annex I attached hereto to join and become a party to the YSB Shareholders Agreement, as amended by the
terms and conditions set forth in this Agreement.

 

Article III

 

AMENDMENT
TO THE YSB SHAREHOLDERS AGREEMENT

 

3.1.            Amendment
and Effectiveness. The Company and the YSB Shareholders hereby agree to amend the YSB Shareholders Agreement as provided in this
Article III (the “YSB SHA Amendments”) and acknowledge and agree that the YSB SHA Amendments are necessary
and desirable and do not adversely affect the rights of any holder of YSB Preferred Shares in a disproportionate and adverse manner.
The YSB SHA Amendments shall automatically take effect, and shall only take effect, as of and from the First Merger Effective Time; provided
that if the Business Combination Agreement is terminated prior to the Closing, the YSB SHA Amendments shall not become effective
and shall be deemed void and shall have no force or effect.

 

3.2.            Certain
Defined Terms. Schedule 4 to the Agreement is amended to add the following defined terms:

 

“Business Combination Agreement”
means the Business Combination Agreement entered into the, dated September 29, 2022, by and among the Company, Merger Sub I, Merger Sub
II and SPAC.

 

“First Merger” means
the merger of Merger Sub I with and into SPAC in accordance with the Business Combination Agreement, with SPAC surviving the merger as
a wholly-owned subsidiary of the Company.

 

“First Merger Effective Time”
means the time when the plan of merger in respect of the First Merger is registered by the Registrar of Companies of the Cayman Islands
or such later time (being not later than the 90th day after registration by the Registrar of Companies of the Cayman Islands) as Merger
Sub I and SPAC may agree and specify pursuant to the Companies Act (As Revised) of the Cayman Islands.

 

“Merger Sub I” means
Oceanview Bioscience Acquisition Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands
and a direct wholly owned subsidiary of the Company.

 

“Merger Sub II”
means Hudson Biomedical Group Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands
and a direct wholly owned subsidiary of the Company.

 

“Ordinary Shares”
shall (i) prior to the First Merger Effective Time, have the meaning specified in Recital A and (ii) after the First Merger
Effective Time, mean ordinary shares of the Company, par value $0.00002 per share.

 

“Second Merger”
means the merger of SPAC, as surviving company in the First merger with and into Merger Sub II in accordance with the Business Combination
Agreement, with Merger Sub II surviving the merger as a wholly-owned subsidiary of the Company.

 

“Second Merger Effective Time”
means the time when the plan of merger in respect of the Second Merger is registered by the Registrar of Companies of the Cayman Islands
or such later time (being not later than the 90th day after registration by the Registrar of Companies of the Cayman Islands) as SPAC
and Merger Sub II may agree and specify pursuant to the Companies Act (As Revised) of the Cayman Islands.

 

    5

     

    

 

“SPAC” means Summit
Healthcare Acquisition Corp., an exempted company limited by shares incorporated under the laws of the Cayman Islands.

 

“SPAC Insider” means
Sponsor, Tao Bai, Thomas Folinsbee and Ian Stone.

 

“Sponsor” means
Summit Healthcare Acquisition Sponsor LLC, a Cayman Islands limited liability company.

 

3.3.            References
to “IPO” and “Qualified IPO”. All references to “IPO” and “Qualified IPO”
in the YSB Shareholders Agreement (including all Exhibits and Schedules thereto) shall be deemed to mean the “First Merger”
and all references to “closing of a Qualified IPO” and “consummation of a Qualified IPO” shall
be deemed to mean “consummation of the First Merger” that occurs at the First Merger Effective Time.

 

3.4.            Lock-Up
Restrictions. The following shall be inserted as a new Section 1A of the YSB Shareholders Agreement:

 

   “1A       SHAREHOLDER
LOCK-UP.

 

(A)        Lock-Up
Restrictions. Subject to Section 1A(B), each Shareholder covenants and agrees not to, during the Applicable Period, without
the prior written consent of the Company in compliance with Section 1A(B), sell, transfer, tender, grant, pledge, assign or otherwise
dispose of (including by gift, tender or exchange offer, merger or operation of law), encumber, hedge or utilize a derivative to transfer
the economic interest in (collectively, “Transfer”), or enter into any agreement, option or other arrangement (including
any profit sharing arrangement) with respect to the Transfer of, any Ordinary Shares held by it as of immediately following the First
Merger Effective Time (the “Lock-Up Shares”); provided, however, that the foregoing shall not apply
to:

 

(a)            Transfers
to a partnership, limited liability company or other entity of which such Shareholder is the legal and beneficial owner of all of the
outstanding equity securities or similar interests;

 

(b)            if
such Shareholder is a natural person, Transfers (A) by gift to any member of such Shareholder’s Immediate Family; (B) to
a family trust, established for the exclusive benefit of such Shareholder or any of his Immediate Family for estate planning purposes;
(C) by virtue of laws of descent and distribution upon death of such Shareholder; or (D) pursuant to a court order or settlement
agreement related to the distribution of assets in connection with the dissolution of marriage or civil union;

 

(c)            if
such Shareholder is not a natural person, Transfers (A) to another Person that is an Affiliate of the Shareholder, or to any investment
fund or other entity Controlling, Controlled by, managing or managed by or under common Control with the Shareholder or its affiliates
or who shares a common investment advisor with the Shareholder; (B) as part of a distribution to members, partners, managers or
shareholders of the Shareholder via dividend, distribution in-kind or share repurchase; or (C) by gift to a charitable organization
or to a charitable foundation;

 

(d)            if
such Shareholder is not a natural person, Transfers by virtue of the Laws of the state of the Shareholder’s organization and the
Shareholder’s organizational documents upon dissolution of the Shareholder;

 

    6

     

    

 

(e)            Transfers
relating to Ordinary Shares or other securities convertible into or exercisable or exchangeable for Ordinary Shares acquired in open
market transactions after the First Merger Effective Time;

 

(f)            the
entry by a Shareholder into any trading plan providing for the sale of Ordinary Shares meeting the requirements of Rule 10b5-1(c) under
the Exchange Act, provided that such plan does not provide for, or permit, the sale of any Ordinary Shares during the Applicable
Period insofar as it relates to the applicable Lock-Up Shares and no public announcement or filing is voluntarily made or required regarding
such plan during the Applicable Period insofar as it relates to the applicable Lock-Up Shares;

 

(g)            Transfers
in the event of completion of a liquidation, merger, exchange of shares or other similar transaction which results in all of the Company’s
shareholders having the right to exchange their Ordinary Shares for cash, securities or other property;

 

(h)            pledges
of Lock-Up Shares by a holder thereof that create a mere security interest in such Lock-Up Shares pursuant to a bona fide loan or indebtedness
transaction so long as such holder continues to control the exercise of the voting rights of such pledged Lock-Up Shares (as well as
any foreclosure on such pledged Lock-Up Shares so long as the transferee in such foreclosure agrees to become a party to this Agreement
and be bound by all lock-up obligations applicable to a Shareholder, provided that such agreement shall only take effect in the
event that the transferee takes possession of the Lock-Up Shares as a result of foreclosure);

 

(i)            filing
of the registration statement on Form F-1 for the resale of Ordinary Shares held by the shareholders of the Company immediately
prior to the First Merger Effective Time and the SPAC Insiders, and filing of the registration statement on Form S-8 for the resale
of Ordinary Shares issuable upon exercise of awards granted or to be granted under the Company’s share incentive plans, provided
that the lock-up restrictions of the relevant Shareholders shall not be released as a result of such filings; and

 

(j)            Transfers
to the Company (1) to satisfy tax withholding obligations pursuant to the Company’s equity incentive plans or arrangements
or (2)  pursuant to any contractual arrangement in effect at the First Merger Effective Time that provides for the repurchase by
the Company or forfeiture of the relevant Shareholder’s Ordinary Shares or other securities convertible into or exercisable or
exchangeable for Ordinary Shares in connection with the termination of such Shareholder’s employment with or service to the Company;

 

provided,
further, however, that in the case of clauses (a) through (d) and (h), these permitted transferees shall enter
into a written agreement, in substantially the form of this Section 1A, agreeing to be bound by the restrictions on Transfer of
Lock-Up Shares applicable to the Transferring Shareholder prior to such Transfer.

 

(B)            No
Amendment or Waiver. The Company shall not amend or waive the lock-up restriction herein with respect to any of the Shareholders,
unless the Company extends such amendment and/or waiver to all Shareholders which are party hereto on the same terms and conditions (including,
for the avoidance of doubt, the timing of any release from such lock-up restriction) and on a pro rata basis. The Company shall provide
at least five (5) Business Days’ advance written notice to all Shareholders which are party hereto of any such amendment or
waiver. Notwithstanding the foregoing, the Shareholders acknowledge and agree that the Company shall have the right to release, (i) in
its sole discretion, up to 3,000,000 Lock-Up Shares (equivalent to an aggregate of 12,000,000 shares of the Company with par value of
US$0.000005 before the First Merger Effective Time) and (ii) with prior written consent from SPAC and Sponsor, an additional number
of Lock-Up Shares (together with such shares under paragraph 1A(B)(i), the “Released Shares”) to the extent necessary
to satisfy the minimum public float requirement as required for obtaining the approval on listing of the Ordinary Shares and the Company’s
warrants on the applicable U.S. stock exchange, from the lock-up restrictions in this Section 1A, in each case, on a pro rata
basis among and only among the Lock-Up Shares held by the Shareholders that hold Preferred Shares or Ordinary Shares issued upon
the conversion of such Preferred Shares and the Share Consolidation (as such term is defined in the Business Combination Agreement) immediately
prior to the First Merger Effective Time, but without extending such amendment and/or waiver to all other shareholders of the
Company on a pro rata basis. For the avoidance of doubt, (i) the Released Shares shall no longer be subject to this Section 1A
after such release in accordance with this Section 1A(B), and the holders of the Released Shares shall have the sole discretion
to exercise, Transfer, assign, dispose of or grant all the rights and obligations of the Released Shares without any further consent
or approval from any of the Company, SPAC, Sponsor or other Shareholders; and (ii) the Company and SPAC, as applicable, shall instruct
the transfer agent to remove the restrictive legends (if any) attached to the Released Shares in respect of the lock-up restrictions
herein upon the release hereunder.

 

    7

     

    

 

(C)            For
the avoidance of doubt, each Shareholder shall retain all of its rights as a shareholder of the Company during the Applicable Period,
including the right to vote any Locked-Up Shares or receive any dividends or distributions thereon.

 

(D)            In
furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the Locked-Up Shares,
are hereby authorized to decline to make any transfer of securities if such Transfer would constitute a violation or breach of the lock-up
restrictions hereunder.

 

(E)            Certain
Definitions. For purposes of this Section 1A:

 

(a)             “Applicable
Period” means the period commencing on the First Merger Effective Time and ending on

 

(1)        with
respect to the Lock-Up Shares of the Shareholders who are not a SPAC Insider, the earlier of (x) 180 days after the First Merger
Effective Time, (y) the date following the First Merger Effective Time on which the Company completes a liquidation, merger, share
exchange or other similar transaction that results in all of the Company’s shareholders having the right to exchange their Ordinary
Shares for cash, securities or other property, and (z) the date on which the last reported sale price of the Ordinary Shares equals
or exceeds $12.00 per share (as adjusted for share splits, share combinations, share dividends, reorganizations, recapitalizations and
the like) for any twenty (20) trading days within any thirty (30) trading day period commencing at least one hundred fifty (150) days
after the First Merger Effective Time; and

 

(2)         with
respect to the Lock-Up Shares of the SPAC Insiders, the earliest of (x) one (1) year after the First Merger Effective Time,
(y) the date following the First Merger Effective Time on which the Company completes a liquidation, merger, share exchange or other
similar transaction that results in all of the Company’s shareholders having the right to exchange their Ordinary Shares for cash,
securities or other property, and (z) the date on which the last reported sale price of the Ordinary Shares equals or exceeds $12.00
per share (as adjusted for share splits, share combinations, share dividends, reorganizations, recapitalizations and the like) for any
twenty (20) trading days within any thirty (30) trading day period commencing at least one hundred fifty (150) days after the First Merger
Effective Time.

 

(b)            “Immediate
Family” means, as to a natural person, such individual’s spouse, former spouse, domestic partner, child (including by
adoption), father, mother, brother or sister, and lineal descendant (including by adoption) of any of the foregoing persons.”

 

    8

     

    

 

3.5.            Sponsor
Board Representation. The following shall be inserted as a new Section 2A of the YSB Shareholders Agreement:

 

“2A          SPONSOR
BOARD REPRESENTATION. Effective as of and from the First Merger Effective Time, Sponsor shall have the right to appoint two (2) persons
as directors to the Board (each, a “Sponsor Director”) so long as Sponsor beneficially owns not less than one percent
(1%) of all the issued and outstanding shares of the Company. A Sponsor Director shall be entitled to attend meetings of the Board and
to receive copies of all notices, minutes, consents and other materials that are provided to the directors on the Board at the same time
and in the same manner as provided to the directors on the Board. In the event of the death, disability, resignation or removal of any
Sponsor Director, Sponsor may designate any other person to replace such Sponsor Director. For the avoidance of doubt, none of the Shareholders
of the Company shall be obliged to vote in favor of any appointment or election of any director of the Company, including, without limitation,
any Sponsor Director, whether such appointment or election is to be made at any shareholders meeting of the Company, by written consent
or otherwise, after the First Merger Effective Time.”

 

3.6.            Registrable
Securities. Section 3.2(b) of the YSB Shareholders Agreement is amended as follows::

 

From:

 

		“(b)	Registrable Securities. The term
                                            “Registrable Securities” means: (1) any Ordinary Shares of the Company
                                            issued or issuable pursuant to conversion of any shares of Preferred Shares, or pursuant
                                            to the Right of Participation (defined in Section 4), and (2) any Ordinary Shares
                                            issued (or issuable upon the conversion or exercise of any warrant, right or other security
                                            which is issued) as a dividend or other distribution with respect to, or in exchange for
                                            or in replacement of, any Preferred Shares described in subparagraph (1) of this subsection
                                            (b). Notwithstanding the foregoing, “Registrable Securities” shall exclude
                                            any Registrable Securities sold by a person in a transaction in which rights under this Section 3
                                            are not assigned in accordance with this Agreement, and any Registrable Securities which
                                            are sold in a registered public offering under the Securities Act or analogous statute of
                                            another jurisdiction, or sold pursuant to Rule 144 promulgated under the Securities
                                            Act or analogous rule of another jurisdiction.”

 

To:

 

“(b)          Registrable
Securities. The term “Registrable Securities” means:

 

(A) any Ordinary Shares of the
Company issued or issuable pursuant to conversion of any Preferred Shares;

 

(B) any Ordinary Shares issued
(or issuable upon the conversion or exercise of any warrant, right or other security which is issued) as a dividend or other distribution
with respect to, or in exchange for or in replacement of, any Shares described in clause (A);

 

(C) any Ordinary Shares issued
(or issuable upon the conversion or exercise of any warrant, right or other security which is issued) to the SPAC Insiders as of immediately
following the First Merger;

 

(D) any Ordinary Shares that
may be acquired by a SPAC Insider upon the exercise of any of the warrants (or any other option or right to acquire Ordinary Shares)
that are held by such SPAC Insider as of immediately following the First Merger; and

 

(E) any other Equity Securities
of the Company issued or issuable with respect to any securities referenced in clauses (A) through (D) by way of a share dividend
or stock split or in connection with a recapitalization, merger, consolidation, spin-off, reorganization or similar transaction;

 

    9

     

    

 

provided,
however, as to any particular Registrable Securities, such securities shall cease to be Registrable Securities when: (i) a
registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities
shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement; (ii) such securities
shall have been otherwise transferred, new certificates for such securities not bearing a legend restricting further transfer shall have
been delivered by the Company and subsequent public distribution of such securities shall not require registration under the Securities
Act; (iii) such securities shall have ceased to be outstanding; (iv) such securities have been sold to, or through, a broker,
dealer or underwriter in a public distribution or other public securities transaction; or (v) such securities become eligible for
resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 promulgated by
the SEC pursuant to the Securities Act.”

 

3.7.            Shelf
Registration. The following shall be inserted as a new Section 3.5A of the YSB Shareholders Agreement:

 

“3.5A
Shelf Registration.

 

	 	(a)	Filing. The Company shall file within 20 days of the Second Merger Effective Time or within
    60 days of the Second Merger Effective Time if the Company is required to include therein additional financial information that is
    not included in the Form F-4 at the time of the Second Merger Effective Time, and use commercially reasonable efforts to cause
    to be declared effective as soon as practicable thereafter within 90 calendar days following the Second Merger Effective Time, but
    if the SEC notifies the Company that the Shelf will not be “reviewed” or will not be subject to further review, such
    effectiveness date shall be no later than the 10th business day after the date the Company is notified (orally or in writing, whichever
    is earlier) by the SEC that the Registration Statement will not be “reviewed” or will not be subject to further review,
    a Registration Statement for a Shelf Registration on Form F-1 or Form S-1, as applicable (the “Form F-1 Shelf”)
    or, if the Company is eligible to use a Registration Statement on Form F-3 or Form S-3, a Shelf Registration on Form F-3
    or Form S-3, as applicable (the “Form F-3 Shelf”, together with the Form F-1 Shelf, the “Shelf”),
    in each case, covering the resale of all the Registrable Securities (determined as of two business days prior to such filing) on
    a delayed or continuous basis; provided, however, that the Company’s obligations to include the Registrable Securities held
    by a holder of Registrable Securities (the “Holder”) in the Shelf are contingent upon such Holder furnishing in
    writing to the Company such information regarding the Holder, the securities of the Company held by the Holder and the intended method
    of disposition of the Registrable Securities as shall be reasonably requested by the Company to effect the registration of the Registrable
    Securities, and the Holder shall execute such documents in connection with such registration as the Company may reasonably request
    that are customary of a selling shareholder in similar situations. Such Shelf shall provide for the resale of the Registrable Securities
    included therein pursuant to any method or combination of methods legally available to, and requested by, any Holder named therein.
    The Company shall maintain a Shelf in accordance with the terms hereof, and shall prepare and file with the SEC such amendments,
    including post-effective amendments, and supplements as may be necessary to keep a Shelf continuously effective, available for use
    and in compliance with the provisions of the Securities Act until such time as there are no longer any Registrable Securities in
    such Shelf. In the event the Company files a Form F-1 Shelf, the Company shall use its commercially reasonable efforts to convert
    the Form F-1 Shelf (and any Subsequent Shelf Registration) to a Form F-3 Shelf as soon as practicable after the Company
    is eligible to use Form F-3. References to Section 3.5 in Section 3.10 of the YSB Shareholders Agreement shall exclude
    this Section 3.5A.

 

    10

     

    

 

	 	(b)	Subsequent Shelf Registration. If any Shelf ceases to be effective under the Securities Act for any
    reason at any time while Registrable Securities are still outstanding, the Company shall use its commercially reasonable efforts
    to as promptly as is reasonably practicable cause such Shelf to again become effective under the Securities Act (including obtaining
    the prompt withdrawal of any order suspending the effectiveness of such Shelf), and shall use its commercially reasonable efforts
    to as promptly as is reasonably practicable amend such Shelf in a manner reasonably expected to result in the withdrawal of any order
    suspending the effectiveness of such Shelf or file an additional registration statement as a Shelf (a “Subsequent Shelf
    Registration”) registering the resale of all Registrable Securities (determined as of two business days prior to such filing),
    and pursuant to any method or combination of methods legally available to, and requested by, any Holder named therein. If a Subsequent
    Shelf Registration is filed, the Company shall use its commercially reasonable efforts to (i) cause such Subsequent Shelf Registration
    to become effective under the Securities Act as promptly as is reasonably practicable after the filing thereof (it being agreed that
    the Subsequent Shelf Registration shall be an automatic shelf registration statement (as defined in Rule 405 promulgated under
    the Securities Act) if the Company becomes a well-known seasoned issuer (as defined in Rule 405 promulgated under the Securities
    Act) at the most recent applicable eligibility determination date), and (ii) keep such Subsequent Shelf Registration continuously
    effective, available for use and in compliance with the provisions of the Securities Act until such time as there are no longer any
    Registrable Securities included in such Subsequent Shelf Registration. Any such Subsequent Shelf Registration shall be on Form F-3
    or Form S-3, as applicable, to the extent that the Company is eligible to use such form. Otherwise, such Subsequent Shelf Registration
    shall be on another appropriate form.
	 	 	 
	 	(c)	Underwriting. If the Holders of Registrable Securities requesting registration under this
    Section 3.5A intend to distribute the Registrable Securities covered by their request by means of an underwriting, the provisions
    of Section 3.3(b) shall apply to such registration.”

 

3.8.            Assignment.
Section 10.1 of the YSB Shareholders Agreement is amended in its entirety and replaced as follows:

 

From:

 

“10.1 Assignment. Notwithstanding
anything herein to the contrary, all rights and obligations of the Preferred Holders (in their capacity as a Preferred Holder or otherwise)
may be assigned to any Person to which the Preferred Holders transfer their Preferred Shares in accordance with this Agreement; provided,
however, that no party, other than the Preferred Holders and its Affiliates, may be assigned any of the foregoing rights unless the Company
is given written notice by the assigning party stating the name and address of the assignee and identifying the securities of the Company
as to which the rights in question are being assigned.”

 

To:

 

“10.1 Assignment. Except
as otherwise provided in this Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon
the respective permitted successors and assigns of the parties (including transferees of any Registrable Securities). Nothing in this
Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and
assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this
Agreement.”

 

    11

     

    

 

3.9.            Amendment
and Modification. Section 10.2 of the YSB Shareholders Agreement is amended by adding the following bolded and underlined
text:

 

“10.2 Amendment of Rights.
Any provision in this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance
and either retroactively or prospectively), only by the written consent of (i) as to the Company, only by the Company; (ii) as
to the Series A Holders, only by the Majority Series A Holders (and the relevant holders of the Ordinary Shares which the Series A
Preferred Shares have been converted into), provided, however, that any Series A Holder may waive any of its own rights hereunder
without obtaining the consent of any other Series A Holders, provided further, that any amendment or waiver that effects any Series A
Holder in a disproportionate and adverse manner than the effect of such amendment or waiver on any other Series A Holders shall
require the written consent of the holder so disproportionately and adversely affected; (iii) as to the Series B Holders, only
by the Majority Series B Holders (and relevant holders of the Ordinary Shares which the Series B Preferred Shares have been
converted into), provided, however, that any Series B Holder may waive any of its own rights hereunder without obtaining the consent
of any other Series B Holders; provided further, that any amendment or waiver that affects any Series B Holder in a disproportionate
and adverse manner than the effect of such amendment or waiver on any other Series B Holders shall require the written consent of
the holder so disproportionately and adversely affected, and (iv) as to the Ordinary Holders, by person or entities holding at least
a majority of the outstanding Ordinary Shares; provided, however, that any Ordinary Holder may waive any of its own rights hereunder
without obtaining the consent of any other Ordinary Holders. Any amendment or waiver effected in accordance with this Section 10
shall be binding upon the Company, the Series A Holders, the Series B Holders, the Ordinary Holders and their respective permitted
transferees. Notwithstanding the foregoing and anything to the contrary contained herein, (i) only upon the prior written
consent of the Company and the Holders of at least a majority of the Registrable Securities at the time in question, compliance with
any of the provisions, covenants and conditions set forth in Section 3 (Registration Rights) of this Agreement may be waived, or
any of such provisions, covenants or conditions may be amended or modified; provided, however, that any amendment or modification to
Section 3 (Registration Rights) of this Agreement that would have a disproportionately adverse effect on any party’s rights
hereunder in any material respect shall require the prior written consent of such party, and (ii) no amendment or modification shall
be made to Section 2A (Sponsor Board Representation) without Sponsor’s prior written consent.”

 

3.10.            Termination
Upon First Merger. The following shall be inserted as a new Section 12.14 of the YSB Shareholders Agreement:

 

“12.14 Termination upon First
Merger. Section 1 (Information Rights and Inspection Rights), Section 2 (Board Representation), Section 4 (Right of
Participation), Section 5 (Transfer Restrictions), Section 6 (Confidentiality and Non-Disclosure), Section 7 (Protective
Provisions), Section 8A (Conversion Rights), Section 9A (Liquidation Preference), Section 9B (Redemption) and Section 11
(Other Undertakings of the Company and the Founders), except for Section 11.5 (Use of Preferred Holders’ Name or Logo), of
this Agreement shall be automatically terminated effective as of the First Merger Effective Time, and thereupon shall be of no further
force or effect, without any further action on the part of any of the Shareholders or the Company, and neither the Company, the Shareholders,
nor any of their respective affiliates or subsidiaries shall have any further rights, duties, liabilities or obligations thereunder and
each Shareholder and the Company hereby releases in full any and all claims with respect thereto with effect on and from the First Merger
Effective Time.”

 

3.11.            Additional
Parties. The following shall be inserted as a new Section 12.15 of the YSB Shareholders Agreement and the Exhibit A
referred to therein shall be in the form of Annex I hereto:

 

“12.15 Deed of Adherence.
Each Shareholder and its permitted transferees (if not already a party to this Agreement) may, upon execution and delivery to the Company
of a Deed of Adherence substantially in the form attached hereto as Exhibit A, become a party to this Agreement, as if it had been
a Party to this Agreement as of the date thereof and shall be subject to all of the rights, obligations, and restrictions described in
this Agreement.”

 

    12

     

    

 

3.12.            Miscellaneous.
Each of Section 3.1, Section 3.14 and Section 3.15 of the YSB Shareholders Agreement is deleted in its entirety and replaced
as follows, respectively:

 

From:

 

“3.1          Applicability
of Rights. The Preferred Holders shall be entitled to the following rights with respect to any potential public offering of the Company’s
Ordinary Shares in the United States and shall be entitled to reasonably analogous or equivalent rights with respect to any other offering
of the Company’s securities in any other jurisdiction in which the Company undertakes to publicly offer or list such securities
for trading on a recognized securities exchange.”

 

“3.14        Qualified
IPO. The Company and the Founder shall use their best efforts to complete, or cause to complete, a Qualified IPO prior to January 28,
2024.”

 

“3.15        Preferred
Holders’ Right to Sell Shares in a Public Offering. Preferred Holders hereby agree not to transfer or sell their shares in
the IPO of the Company, unless otherwise agreed on by the Company.”

 

To:

 

“3.1          [Intentionally
Omitted.]”

 

“3.14        [Intentionally
Omitted.]”

 

“3.15        [Intentionally
Omitted.]”

 

Article IV

 

Additional
Agreements of the Parties

 

4.1.            Sponsor
Share Forfeiture and Conversion. Sponsor hereby agrees that immediately prior to the First Merger Effective Time, Sponsor shall surrender
to SPAC an aggregate of 1,446,525 SPAC Class B Ordinary Shares for cancellation at no cost (the “Sponsor Share Forfeiture”).
Immediately following the completion of the Sponsor Share Forfeiture and before the First Merger Effective Time, Sponsor will hold an
aggregate of 3,853,475 SPAC Class B Ordinary Shares, and all such shares will be exchanged for ordinary shares of the Company, par
value $0.00002 per share, on a one-for-one basis in connection with the First Merger (the “Sponsor Share Conversion”).
Notwithstanding the foregoing, if (i) after completion of the Sponsor Share Forfeiture, the First Merger does not occur and the
Business Combination Agreement is terminated, or (ii) after completion of the First Merger, the Second Merger does not occur and
the Business Combination Agreement is terminated, each of SPAC, Sponsor and the Company shall take all such actions that are necessary,
proper or advisable under applicable Laws such that Sponsor shall, to the fullest extent possible, be returned to the position in which
Sponsor would have been, and would be entitled to all rights and benefits that Sponsor would have had, as if the Sponsor Share Forfeiture
and the Sponsor Share Conversion, as the case may be, had not occurred.

 

4.2.            Sponsor
Affiliate Agreements. Each of Sponsor and SPAC hereby agree that from the date hereof until the termination of this Agreement, none
of them shall, or shall agree to, amend, modify or vary that certain letter agreement dated June 8, 2021 by and among the Sponsor,
SPAC and other SPAC Shareholders, except as otherwise provided for under this Agreement, the Business Combination Agreement or any other
Transaction Documents.

 

4.3.            Existing
Shareholder Rights. Each of the YSB Shareholders and the Company hereby agrees that, (i) after the First Merger Effective
Time, except as set forth in the YSB Shareholders Agreements and the Amended Company Charter, any rights under any other agreement providing
for right of first refusal, right of first offer, participation rights, redemption rights, put rights, purchase rights or other similar
rights not generally available to the shareholders of the Company, if any, shall be automatically terminated effective as of the First
Merger Effective Time, and thereupon shall be of no further force or effect, without any further action on the part of any of the YSB
Shareholders or the Company, and neither the Company, the YSB Shareholders, nor any of their respective affiliates or subsidiaries shall
have any further rights, duties, liabilities or obligations thereunder and (ii) from the date hereof until the termination of this
Agreement, none of them shall, or shall agree to, amend, modify or vary the YSB Shareholders Agreement without Sponsor’s prior
written consent, except as otherwise provided for under this Agreement, the Business Combination Agreement or any other Transaction Documents.
For the avoidance of doubt, after the effectiveness of the YSB SHA Amendments, none of the shareholders of the Company will have redemption
rights that are not generally available to the shareholders of the Company.

 

    13

     

    

 

4.4.            Termination
of Prior SPAC Agreement. Each of SPAC, Sponsor and other SPAC Insiders hereby agrees that the Prior SPAC Agreement shall terminate
as of the First Merger Effective Time, and thereafter shall be of no further force and effect.

 

4.5.            Non-Recourse.
This Agreement may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement
or the transactions contemplated hereby may only be brought against, the entities that are expressly named as parties hereto and then
only with respect to the specific obligations set forth herein with respect to such party. Except to the extent a party hereto (and then
only to the extent of the specific obligations undertaken by such party in this Agreement), or its successor or transferee, (a) no
past, present or future director, officer, employee, incorporator, member, partner, shareholder, stockholder, Affiliate, agent, attorney,
advisor or other Representative of any party hereto and (b) no past, present or future director, officer, employee, incorporator,
member, partner, shareholder, stockholder, Affiliate, agent, attorney, advisor or other representative of any of the foregoing shall
have any liability (whether in contract, tort, equity or otherwise) for any one or more of the representations, warranties, covenants,
agreements or other obligations or liabilities of any of the SPAC, the Company, or the Shareholders under this Agreement or for any claim
based on, arising out of, or related to this Agreement or the transactions contemplated hereby.

 

4.6.            Additional
Matters. Each Shareholder shall, from time to time, refrain from exercising any veto right, consent right or similar right
(whether under the Company Charter or the Cayman Act) which would impede, disrupt, prevent or otherwise adversely affect the consummation
of the Mergers or any other Transaction.

 

4.7.            Fiduciary
Duties. Notwithstanding anything in this Agreement to the contrary, nothing herein will be construed to limit or affect any
action or inaction by any Shareholder or SPAC Insider serving as a director, officer, employee or fiduciary of SPAC or the Company (as
the case may be).

 

4.8.            Sponsor
Reimbursement. If the SPAC Transaction Expenses or SPAC’s operating expenses exceed the applicable maximum amounts agreed
between the Company and SPAC in accordance with section 11.6 of the Business Combination Agreement, Sponsor shall, at the Closing, reimburse
SPAC or the Company for the expenses in excess of such mutually agreed amounts. Sponsor may elect to satisfy its foregoing reimbursement
obligation (if any) by (i) cash payment or (ii) cancellation of amounts then outstanding under the Working Capital Loan.

 

Article V

 

General
Provisions

 

5.1.            Notice.
All general notices, demands or other communications required or permitted to be given or made hereunder (“Notices”)
shall be in writing and delivered personally or sent by courier or sent by electronic mail to the intended recipient thereof. Any such
Notice shall be deemed to have been duly served (a) if given personally or sent by local courier, upon delivery during normal business
hours at the location of delivery or, if later, then on the next Business Day after the day of delivery; (b) if sent by electronic
mail during normal business hours at the location of delivery, immediately, or, if later, then on the next Business Day after the day
of delivery; or (c) the third Business Day following the day sent by reputable international overnight courier (with written confirmation
of receipt). Any notice or communication under this Agreement must be given to the Company and SPAC in accordance with Section 11.3
of the Business Combination Agreement and to each Shareholder at its address set forth set forth opposite such Shareholder’s name
on Schedule A or Schedule B hereto (or at such other address for a party as shall be specified by like Notice).

 

5.2.            Assignment;
No Third Party Beneficiaries. This Agreement and the rights, duties and obligations of the Company hereunder may not be assigned
or delegated by the Company in whole or in part. This Agreement and the provisions hereof shall be binding upon and shall inure to the
benefit of each of the parties and its successors and the permitted assigns. This Agreement shall not confer any rights or benefits on
any persons that are not parties hereto, other than as expressly set forth in this Agreement (including Section 4.5 hereof).

 

    14

     

    

 

5.3.            Severability.
The invalidity or unenforceability of any specific provision of this Agreement shall not invalidate or render unenforceable any of its
other provisions. The parties hereto further agree that if any provision contained in this Agreement is, to any extent, held invalid
or unenforceable in any respect under the laws governing this Agreement, they shall take any actions necessary to render the remaining
provisions of this Agreement valid and enforceable to the fullest extent permitted by law and, to the extent necessary, shall amend or
otherwise modify this Agreement to replace any provision contained in this Agreement that is held invalid or unenforceable with a valid
and enforceable provision giving effect to the intent of the parties hereto.

 

5.4.            Entire
Agreement. This Agreement (together with the Business Combination Agreement, the YSB Shareholders Agreement, and including
all agreements entered into pursuant hereto or thereto or referenced herein or therein and all certificates and instruments delivered
pursuant hereto and thereto) set forth the entire understanding of the parties with respect to the subject matter hereof and supersede
all other prior and contemporaneous agreements and understandings between the parties, whether oral or written, with respect to such
subject matter.

 

5.5.            Governing
Law; Venue. Notwithstanding the place where this Agreement may be executed by any of the parties hereto, the parties expressly
agree that this Agreement shall be governed by and construed under the Laws of the State of New York as applied to agreements among New
York residents entered into and to be performed entirely within New York, without regard to the conflict of law provisions of such jurisdiction
and the venue for any action taken with respect to this Agreement shall be any state or federal court in the State of New York.

 

5.6.            WAIVER
OF TRIAL BY JURY. EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY ACTION, SUIT,
COUNTERCLAIM OR OTHER PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH OR RELATING TO THIS AGREEMENT,
THE TRANSACTIONS CONTEMPLATED HEREBY, OR THE ACTIONS OF THE SPONSOR IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.

 

5.7.            Construction.
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rule of
strict construction will be applied against any party. Unless the context otherwise requires: (a) “or” is disjunctive
but not exclusive; (b) words in the singular include the plural, and in the plural include the singular; (c) the words “hereof,”
 “herein,” “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole
and not to any particular provision of this Agreement, and section and subsection references are to this Agreement unless otherwise specified;
(d) the term “including” is not limiting and means “including without limitation”; (e) whenever the
context requires, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms; (f) references to
agreements and other documents shall be deemed to include all subsequent amendments and other modifications or supplements thereto; and
(g) references to statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall
be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation. The
headings, subheadings and captions contained in this Agreement are included for convenience of reference only, and in no way define,
limit or describe the scope of this Agreement or the intent of any provision hereof.

 

5.8.            Amendments
and Modifications. Only upon the prior written consent of (i) the Company, (ii) SPAC, (iii) Sponsor, (iv) YSB
Shareholders holding at least fifty percent (50%) of the then outstanding YSB Ordinary Shares, (v) the Majority Series A Holders
(as defined in the YSB Shareholders Agreement) and (vi) the Majority Series B Holders (as defined in the YSB Shareholders Agreement)
(collectively, the “Consent Parties”), compliance with any of the provisions, covenants and conditions set forth in
this Agreement may be waived, or any of such provisions, covenants or conditions may be amended or modified; provided, however,
that notwithstanding the foregoing, any amendment or modification to this Agreement that would have a disproportionately adverse effect
on any party’s rights hereunder in any material respect shall require the prior written consent of such party.

 

5.9.            Counterparts.
This Agreement may be executed in multiple counterparts (including by electronic means), each of which shall be deemed an original, and
all of which together shall constitute the same instrument, but only one of which need be produced.

 

    15

     

    

 

5.10.          Termination.
This Agreement shall automatically terminate upon the earliest of (i) the First Merger Effective Time (provided, however,
that upon such termination, Article III, Article IV and Article V shall survive indefinitely), (ii) the termination
of the Business Combination Agreement in accordance with its terms and (iii) the 270th day after the date hereof (and if such 270th
day shall not be a Business Day, then the next following Business Day), or such later date as otherwise agreed in writing by the Consent
Parties, and upon such termination, no party shall have any liability hereunder other than for its actual fraud or for its willful and
material breach of this Agreement prior to such termination. Each Shareholder shall have the right to elect, in his, her or its sole
discretion, to terminate its own obligations under Article II of this Agreement if the Business Combination Agreement is amended
without the prior written consent of such Shareholder such that, after giving effect to all such amendments, the consideration payable
or issuable to such Shareholder under the Business Combination Agreement is decreased (either in terms of share number or ownership percentage)
or the form of consideration is changed, including any change to the Share Consolidation Factor or the terms of the Share Consolidation.

 

[Signature
pages follow]

 

    16

     

    

 

In
Witness Whereof, each party has duly executed and delivered this Agreement, all as of the date first written above as a deed.

 

	EXECUTED AND DELIVERED
    AS A DEED for and on behalf of:	 
	 	 
	YishengBio Co., Ltd.	 
	 	 
	Signature:	/s/ Zhang Yi	 

 

	Name:	Zhang Yi	 
	 	 
	Title:	Director	 

 

	In the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/ Zhang Chi	 

 

	 	 
	Printed Name:	Zhang Chi	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

     

     

    

 

In
Witness Whereof, each party has duly executed and delivered this Agreement, all as of the date first written above as a deed.

 

	EXECUTED AND DELIVERED
    AS A DEED for and on behalf of:	 
	 	 
	Summit
    Healthcare Acquisition Corp.	 
	 	 
	Signature:	/s/ Ken Poon	 

 

	Name:	Ken Poon	 
	 	 
	Title:	President	 

 

	In the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/ Tracy Kung	 

 

	 	 
	Printed Name:	Tracy Kung	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

     

     

    

 

In
Witness Whereof, each party has duly executed and delivered this Agreement, all as of the date first written above as a deed.

 

 

	EXECUTED AND DELIVERED
    AS A DEED for and on behalf of:	 
	 	 
	Summit
    Healthcare Acquisition Sponsor LLC	 
	 	 
	Signature:	/s/ Bo Tan	 

 

	Name:	Bo Tan	 
	 	 
	Title:	Manager	 

 

	In the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/ Liu Yingwa	 

 

	 	 
	Printed Name:	Liu Yingwa	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

     

     

    

 

In
Witness Whereof, each party has duly executed and delivered this Agreement, all as of the date first written above as a deed.

 

	EXECUTED AND DELIVERED AS A DEED by:
	 
	TAO BAI, solely
    in his capacity as a shareholder of SPAC

 

	Signature:	/s/ Tao Bai	 

 

	In the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/ Xue Jiang	 

 

	 	 
	Printed Name:	Xue Jiang	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

     

     

    

 

In
Witness Whereof, each party has duly executed and delivered this Agreement, all as of the date first written above as a deed.

 

	EXECUTED AND DELIVERED
    AS A DEED by:	 
	 	 
	THOMAS
    FOLINSBEE, solely in his capacity
    as a shareholder of SPAC	 

 

	Signature:	/s/ Thomas Folinsbee	 

 

	In the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/ Sachiko Folinsbee	 

 

	 	 
	Printed Name:	Sachiko Folinsbee	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

     

     

    

 

In
Witness Whereof, each party has duly executed and delivered this Agreement, all as of the date first written above as a deed.

 

	EXECUTED AND DELIVERED
    AS A DEED by:	 
	 	 
	IAN
    STONE, solely in his capacity as a
    shareholder of SPAC	 

 

	Signature:	/s/ Ian Stone	 

 

	In the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/ Tracy Kung	 

 

	 	 
	Printed Name:	Tracy Kung	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

     

     

    

 

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	ALL
    BRILLIANCE INVESTMENTS LIMITED	 
	 	 
	Signature:	/s/
    Yi Zhang	 
	Name:	Yi
    Zhang	 
	Title:	Authorized
    Signatory	 
	Date:	September 29, 2022 	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Chi Zhang	 
	Printed
    Name:	Chi
    Zhang	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	HOPEFUL
    WORLD COMPANY LIMITED	 
	 	 
	Signature:	/s/
    Rui Mi 	 
	Name:	Rui
    Mi 	 
	Title:	Authorized
    Signatory	 
	Date:	September
29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Nan Zhang 	 
	Printed
    Name:	Nan
    Zhang 	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	APEX
    PRIDE GLOBAL LIMITED	 
	 	 
	Signature:	/s/
    Xu Zhang	 
	Name:	Xu
    Zhang	 
	Title:	Authorized
    Signatory	 
	Date:	September
29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Thomas Coton	 
	Printed
    Name:	Thomas
    Coton	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	ACTION
    TOWN INTERNATIONAL LIMITED	 
	 	 
	Signature:	/s/
    Nan Zhang 	 
	Name:	Nan
    Zhang 	 
	Title:	Authorized
    Signatory	 
	Date:	September
29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Rui Mi	 
	Printed
    Name:	Rui
    Mi	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED

 

	ZHANG
    YI	 
	 	 
	Signature:	/s/
    Zhang Yi 	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Ziyi Li 	 
	Printed
    Name:	Ziyi
    Li 	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED

 

	HUI
    SHAO	 
	 	 
	Signature:	/s/
    Hui Shao 	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Ziyi Li 	 
	Printed
    Name:	Ziyi
    Li 	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED

 

	CHUNYUAN
    WU	 
	 	 
	Signature:	/s/
    Chunyuan Wu	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Chenyu Wu	 
	Printed
    Name:	Chenyu
    Wu	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED

 

	AJIT
    SHETTY	 
	 	 
	Signature:	/s/
    Ajit Shetty	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Christine Clerinx 	 
	Printed
    Name:	Christine
    Clerinx 	 

 

EXECUTED
AND DELIVERED AS A DEED

 

	CHRISTINE
    CLERINX	 
	 	 
	Signature:	/s/
    Christine Clerinx	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Ajit Shetty 	 
	Printed
    Name:	Ajit
    Shetty 	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED

 

	STANLEY
    YI CHANG	 
	 	 
	Signature:	/s/
    Stanley Yi Chang	 
	Date:	September
29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Lanulo Wu	 
	Printed
    Name:	Lanulo
    Wu	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED

 

	AJIT
    SHETTY	 
	 	 
	Signature:	/s/
    Ajit Shetty	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Christine Clerinx	 
	Printed
    Name:	Christine
    Clerinx	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	GENNEX
    CHINA GROWTH FUND	 
	 	 
	Signature:	/s/
    Chan Tsang Tao Oswald	 
	Name:	Chan
    Tsang Tao Oswald	 
	Title:	Director	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Chan Tsang	 
	Printed
    Name:	Chan
    Tsang	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	Mountainview
    Investment Holdings LLC	 
	 	 
	Signature:	/s/
    Hui Shao	 
	Name:	Hui
    Shao	 
	Title:	Manager	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Ziyi Li	 
	Printed
    Name:	Ziyi
    Li	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	Asia
    Ventures II L.P.
	 
	By:	Asia
    Partners II, L.P., its General Partner
	By:	Eight
    Roads GP as General Partner

 

	Signature:	/s/
    Driaan Viljoen	 
	Name:	Driaan
    Viljoen	 
	Title:	Director	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Elizabeth Hickmott	 
	Printed
    Name:	Elizabeth
    Hickmott	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	F-Prime
    Capital Partners Healthcare Fund III LP
	 
	By:	F-Prime
    Capital Partners Healthcare Advisors Fund III LP, its general partner
	By:	Impresa
    Management LLC, its general partner

 

	Signature:	/s/
    Mary Bevelock Pendergast	 
	Name:	Mary
    Bevelock Pendergast	 
	Title:	Vice
    President	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Laura Wysk	 
	Printed
    Name:	Laura
    Wysk	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

 

	OrbiMed
    New Horizons Master Fund, L.P.
	 
	By:	OrbiMed
    New Horizons GP LLC, its General Partner
	By:	OrbiMed
    Advisors LLC, its Managing Member

 

	By:	/s/
    Xuan (Stella) Xing	 
	Name:	Xuan
    (Stella) Xing	 
	Title:	Authorized
    Signatory	 
	Date:	September
29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Tianqi Leng	 
	Name:	Tianqi
    Leng	 

(Print above)

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	Epiphron
    Capital (Hong Kong) Limited	 
	 	 
	Signature:	/s/
    Sherry Xiaoyu Liu	 
	Name:	Sherry
    Xiaoyu Liu	 
	Title:	Authorized
    Signatory	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Wang Ping	 
	Printed
    Name:	Wang
    Ping	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	3W
    Global Investment Limited	 
	 	 
	Signature:	/s/
    Wu Weiwei	 
	Name:	Wu
    Weiwei	 
	Title:	Director	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Jerry Chen	 
	Printed
    Name:	Jerry
    Chen	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	Oceanpine
    Investment Fund II LP	 
	 	 
	Signature:	/s/
    Dongjun Ma	 
	Name:	Dongjun
    Ma	 
	Title:	Authorized
    Signatory	 
	Date:	September
29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Jing Gao	 
	Printed
    Name:	Jing
    Gao	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	3W
    Global Fund	 
	 	 
	Signature:	/s/
    Wu Weiwei	 
	Name:	Wu
    Weiwei	 
	Title:	Director	 
	Date:	September
29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Jenny Chen	 
	Printed
    Name:	Jenny
    Chen	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	MSA
    China Growth Fund II L.P.	 
	 	 
	Signature:	/s/
    Yu Zeng	 
	Name:	Yu
    Zeng	 
	Title:	Authorized
    Signatory	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Ji Qi	 
	Printed
    Name:	Ji
    Qi	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	Superstring
    Capital Master Fund LP	 
	 	 
	Signature:	/s/
    Ting Guo	 
	Name:	Ting
    Guo	 
	Title:	Managing
    Partner	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Wendy Wang	 
	Printed
    Name:	Wendy
    Wang	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	Wudaokou
    Capital Limited	 
	 	 
	Signature:	/s/
    Shen Youchang	 
	Name:	Shen
    Youchang	 
	Title:	Representative	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Shen Linsheng	 
	Printed
    Name:	Shen
    Linsheng	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In 
Witness Whereof,
each party has duly executed and delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED AND DELIVERED AS
A DEED for and on behalf of:

 

ADJUVANT GLOBAL HEALTH TECHNOLOGY
FUND DE, L.P.

 

	Signature:	/s/
Kabeer Aziz	 
	Name:	Kabeer Aziz	 
	Title:	Vice President
 & Secretary	 
	Date:	September 29,
2022	 

 

In the presence of:

 

Witness

 

	Signature:	/s/
Glenn Rockman	 
	Printed
    Name:	Glenn Rockman	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

     

     

    

 

In Witness
Whereof, each party has duly executed and delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

ADJUVANT GLOBAL HEALTH TECHNOLOGY
FUND, L.P.

 

	Signature:	/s/
Kabeer Aziz	 
	Name:	Kabeer Aziz	 
	Title:	Vice President
 & Secretary	 
	Date:	September 29,
2022	 

 

In the presence of:

 

Witness

 

	Signature:	/s/
Glenn Rockman	 
	Printed
    Name:	Glenn Rockman	 

 

Signature
Page to Shareholder Support Agreement and Deed

 

     

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

  

	OrbiMed
    Genesis Master Fund, L.P.
	 
	By:	OrbiMed
    Genesis GP LLC, its General Partner
	By:	OrbiMed
    Advisors LLC, its Managing Member
	 	 

	By:	/s/
    Xuan (Stella) Xing	 
	Name:	Xuan
    (Stella) Xing	 
	Title:	Authorized
    Signatory	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Tianqi Leng	 
	Name:	Tianqi
    Leng	 

 

(Print
above)

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	The
    Biotech Growth Trust PLC
	 
	By:	OrbiMed
    Capital LLC, solely in its capacity as Portfolio Manager
	 	 

	By:	/s/
    Xuan (Stella) Xing	 
	Name:	Xuan
    (Stella) Xing	 
	Title:	Authorized
    Signatory	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Tianqi Leng	 
	Name:	Tianqi
    Leng	 

 

(Print
above)

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	OrbiMed
    Partners Master Fund Limited
	 
	By:	OrbiMed
    Capital LLC, solely in its capacity as Investment Advisor

 

	By:	/s/
    Xuan (Stella) Xing	 
	Name:	Xuan
    (Stella) Xing	 
	Title:	Authorized
    Signatory	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Tianqi Leng	 
	Name:	Tianqi
    Leng	 

 

(Print
above)

 

Signature
Page to Shareholder Support Agreement and Deed

 

    	 	 	 

     

    

 

In
Witness Whereof, each party has duly executed and
delivered this Agreement, all as of the date first written above as a deed.

 

EXECUTED
AND DELIVERED AS A DEED for and on behalf of:

 

	OrbiMed
    Partners SPV, Ltd.
	 
	By:	OrbiMed
    Capital LLC, solely in its capacity as Investment Manager

 

	By:	/s/
    Xuan (Stella) Xing	 
	Name:	Xuan
    (Stella) Xing	 
	Title:	Authorized
    Signatory	 
	Date:	September 29, 2022	 

 

	In
    the presence of:	 
	 	 
	Witness	 
	 	 
	Signature:	/s/
    Tianqi Leng	 
	Name:	Tianqi
    Leng	 

 

(Print
above)

 

Signature
Page to Shareholder Support Agreement and DeedExhibit 10.2

 

WARRANT
ASSIGNMENT AGREEMENT

Among

Summit HEALTHCARE ACQUISITION CORP.,

Yishengbio co., ltd.

and

CONTINENTAL STOCK TRANSFER & TRUST COMPANY

 

Dated
September 29, 2022

 

This
Warrant Assignment Agreement (this “Agreement”), dated September 29,
2022, is made by and among Summit Healthcare Acquisition Corp., a Cayman Islands
exempted company (“SPAC”), YishengBio Co., Ltd.,
a Cayman Islands exempted company (the “Company”), and Continental
Stock Transfer & Trust Company, a New York corporation, as warrant agent (in such capacity, the “Warrant
Agent”) and amends the Warrant Agreement (the “Existing Warrant Agreement”), dated June 8,
2021, by and between SPAC and the Warrant Agent. Capitalized terms used but not defined herein shall have the meaning ascribed to such
terms in the Existing Warrant Agreement.

 

Whereas,
as of the date hereof and pursuant to the Existing Warrant Agreement, (i) SPAC issued (a) 6,000,000 Private Placement Warrants
to the Sponsor and (b) 10,000,000 Public Warrants; and (ii) SPAC expects to issue (a) 750,000 Forward Purchase Warrants
pursuant to the Forward Purchase Agreements (as amended by the respective deed of amendment dated as of the date hereof) and (b) up
to 10,000,000 Public Warrants upon separation of 20,000,000 Units issued and outstanding as of the date hereof.

 

Whereas,
on the date of this Agreement, SPAC, the Company, Oceanview Bioscience Acquisition Co., Ltd., a Cayman Islands exempted company
(“Merger Sub I”), and Hudson Biomedical Group Co., Ltd., a Cayman Islands exempted company (“Merger
Sub II”), entered into a business combination agreement (as amended, modified or supplemented from time to time, the “Business
Combination Agreement”);

 

Whereas,
all of the Warrants are governed by the Existing Warrant Agreement;

 

Whereas,
pursuant to the Business Combination Agreement, Merger Sub I will merge with and into SPAC, with SPAC surviving such merger as a wholly-owned
subsidiary of the Company (the “First Merger”, and the effective time of the First Merger is hereinafter referred
to as the “First Merger Effective Time”), and as a result of the First Merger, the holders of Ordinary Shares
of SPAC shall become holders of ordinary shares of par value US$0.00002 each of the Company (“Company Ordinary Shares”),
and SPAC, as the surviving company in the First Merger, will then merge with and into Merger Sub II (the “Second Merger”),
with Merger Sub II being the surviving entity and a wholly-owned subsidiary of the Company;

 

Whereas,
upon consummation of the First Merger, as provided in Section 4.5 of the Existing Warrant Agreement, the Warrants will no longer
be exercisable for Ordinary Shares but instead will be exercisable (subject to the terms of the Existing Warrant Agreement as amended
hereby) for Company Ordinary Shares;

 

Whereas,
the Board has determined that the consummation of the transactions contemplated by the Business Combination Agreement will constitute
a Business Combination;

 

Whereas,
in connection with the First Merger (as defined in the Business Combination Agreement), SPAC desires to assign all of its right, title
and interest in the Existing Warrant Agreement to the Company and the Company wishes to accept such assignment; and

 

Whereas, Section 9.8 of
the Existing Warrant Agreement provides that SPAC and the Warrant Agent may amend the Existing Warrant Agreement without the consent
of any Registered Holders as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the rights
of the Registered Holders under the Existing Warrant Agreement in any material respect.

 

    1

     

    

 

Now,
Therefore, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1.            Assignment
and Assumption; Consent.

 

1.1            Assignment
and Assumption. As of and with effect on and from the First Merger Effective Time, SPAC hereby assigns to the Company all
of SPAC’s right, title and interest in and to the Existing Warrant Agreement (as amended hereby); and the Company hereby assumes,
and agrees to pay, perform, satisfy and discharge in full, as the same become due, all of SPAC’s liabilities and obligations under
the Existing Warrant Agreement (as amended hereby) arising on, from and after the First Merger Effective Time.

 

1.2            Consent.
The Warrant Agent hereby consents to (i) the assignment of the Existing Warrant Agreement by SPAC to the Company pursuant to Section 1.1 and
the assumption of the Existing Warrant Agreement by the Company from SPAC pursuant to Section 1.1, in each case effective as
of the First Merger Effective Time, and (ii) the continuation of the Existing Warrant Agreement (as amended by this Agreement),
in full force and effect from and after the First Merger Effective Time.

 

2.            Amendment
of Existing Warrant Agreement. Effective as of the First Merger Effective Time, SPAC and the Warrant Agent hereby amend the
Existing Warrant Agreement as provided in this Section 2, and acknowledge and agree that the amendments to the Existing Warrant
Agreement set forth in this Section 2 (i) are necessary and desirable and do not adversely affect the rights of the
Registered Holders under the Existing Warrant Agreement in any material respect and (ii) are to provide for the delivery of Alternative
Issuance pursuant to Section 4.5 of the Existing Warrant Agreement (in connection with the First Merger and the transactions contemplated
by the Business Combination Agreement). If after completion of the First Merger, the Second Merger does not occur and the Business Combination
Agreement is terminated, each of SPAC, the Company and the Warrant Agent shall take all such actions that are necessary, proper or advisable
under applicable Laws such that each of SPAC and the Registered Holders shall, to the fullest extent possible, be returned to the position
in which it would have been, and would be entitled to all rights and benefits that it would have had under the Existing Warrant Agreement,
if the First Merger had not occurred.

 

2.1            References
to the “Company”. All references to the “Company” in the Existing Warrant Agreement
(including all Exhibits thereto) shall be references to the Company (as defined herein).

 

2.2            References
to Ordinary Shares. All references to “Ordinary Shares” in the Existing Warrant Agreement (including
all Exhibits thereto) shall be references to the Company Ordinary Shares.

 

2.3            References
to Business Combination. All references to “Business Combination” in the Existing Warrant Agreement
(including all Exhibits thereto) shall be references to the transactions contemplated by the Business Combination Agreement, and references
to “the completion of the Business Combination” and all variations thereof in the Existing Warrant Agreement (including all
Exhibits thereto) shall be references to the Closing (as defined in the Business Combination Agreement).

 

    2

     

    

 

2.4            Notice
Clause. Section 9.2 of the Existing Warrant Agreement is hereby deleted and replaced with the following:

 

“Notices. Any notice,
statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the
Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier
service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing
by the Company with the Warrant Agent), as follows:

 

YishengBio
Co., Ltd. 

Building No.2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC

Attn: David Hui Shao

Email: [***]

 

Any notice, statement or
demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall
be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within
five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Warrant
Agent with the Company), as follows:

 

Continental Stock Transfer & Trust Company 

One State Street, 30th Floor 

New York, NY 10004 

Attention: Compliance Department”

 

3.            Miscellaneous
Provisions.

 

3.1            Effectiveness
of the Amendment. Each of the parties hereto acknowledges and agrees that the effectiveness of this Agreement shall be expressly
subject to the occurrence of the First Merger and substantially contemporaneous occurrence of the Closing (as defined in the Business
Combination Agreement) and shall automatically be terminated and shall be null and void if the Business Combination Agreement shall be
terminated for any reason.

 

3.2            Successors.
All the covenants and provisions of this Agreement by or for the benefit of the Company, SPAC or the Warrant Agent shall bind and inure
to the benefit of their respective successors and assigns.

 

3.3            Applicable
Law and Exclusive Forum. The validity, interpretation, and performance of this Agreement shall be governed in all respects
by the laws of the State of New York. Subject to applicable law, each of the Company and SPAC hereby agrees that any action, proceeding
or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State
of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive forum for any such action, proceeding or claim. Each of the Company and SPAC hereby waives any
objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions
of this paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for
which the federal district courts of the United States of America are the sole and exclusive forum.

 

Any person or entity purchasing
or otherwise acquiring any interest in the Warrants shall be deemed to have notice of and to have consented to the forum provisions in
this Section 3.3. If any action, the subject matter of which is within the scope the forum provisions above, is filed in a
court other than a court located within the State of New York or the United States District Court for the Southern District of New York
(a “foreign action”) in the name of any warrant holder, such warrant holder shall be deemed to have consented to: (x) the
personal jurisdiction of the state and federal courts located within the State of New York or the United States District Court for the
Southern District of New York in connection with any action brought in any such court to enforce the forum provisions (an “enforcement
action”), and (y) having service of process made upon such warrant holder in any such enforcement action by service upon such
warrant holder’s counsel in the foreign action as agent for such warrant holder.

 

3.4            Counterparts.
This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes
be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. A signed copy of this
Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery
of an original signed copy of this Agreement.

 

    3

     

    

 

3.5            Effect
of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not affect
the interpretation thereof.

 

3.6            Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to
such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

[Signature Pages Follow]

 

    4

     

    

 

 

In
Witness Whereof, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

 

	 	Summit Healthcare
    Acquisition Corp.
	 	 
	 	Signature:	/s/ Ken Poon

 

	 	Name:	Ken Poon
	 	 
	 	Title:	President

 

Signature
Page to Warrant Assignment Agreement

 

     

     

    

 

In
Witness Whereof, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

 

	 	YishengBio
    Co., Ltd.
	 	 
	 	Signature:	/s/ Zhang Yi

 

	 	Name:	Zhang Yi
	 	 
	 	Title:	Director

 

Signature
Page to Warrant Assignment Agreement

 

     

     

    

 

In
Witness Whereof, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

 

	 	Continental
    Stock Transfer & Trust Company,  as
    Warrant Agent
	 	 
	 	Signature:	/s/ Douglas Reed

 

	 	Name:	Douglas Reed
	 	 
	 	Title:	Vice President

 

Signature
Page to Warrant Assignment Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]